These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2460937)

  • 1. [Effect of treatment with mepartricin on the concentrations of androgen receptors in adenomatous human prostatic tissue. Preliminary data].
    Longo A; Fiorelli G; Rizzo M; Tosto A; Natali A; Forti G
    Minerva Urol Nefrol; 1988; 40(2 Suppl):13-5. PubMed ID: 2460937
    [No Abstract]   [Full Text] [Related]  

  • 2. [Can mepartricin be considered an antiandrogenic drug?].
    Lubrano C; Bianchi P; Verna T
    Minerva Urol Nefrol; 1992; 44(2):113-6. PubMed ID: 1384153
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of treatment with mepartricin on the plasma androgen and gonadotropin concentrations in subjects with benign prostatic hypertrophy].
    Sciarra F; Bianchi P; Toscano V
    Minerva Urol Nefrol; 1988; 40(2 Suppl):10-2. PubMed ID: 2460936
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical pharmacologic aspects of mepartricin. Possible pharmacologic interference with digitaloids and anticoagulants].
    Costa FV
    Minerva Urol Nefrol; 1988; 40(2 Suppl):5-6. PubMed ID: 2460951
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapeutic usefulness of mepartricin in benign prostatic hypertrophy: 2 years' experience. Preliminary note on the effect of mepartricin on certain possible etiopathogenic factors in benign prostatic hypertrophy].
    Mirone V; Prezioso D; Palmieri A; Bocchini P
    Minerva Urol Nefrol; 1988; 40(2 Suppl):16-7. PubMed ID: 2460938
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of mepartricin treatment on the concentrations of the receptors for the insulin-like growth factor-I (IGF-I) in human adenomatous tissue].
    Longo A; Fiorelli G
    Minerva Urol Nefrol; 1992; 44(1):31-3. PubMed ID: 1382321
    [No Abstract]   [Full Text] [Related]  

  • 7. [Urination disorders, endocrine features and sexual activity in patients with benign prostatic hypertrophy under treatment with mepartricin].
    Scarpa RM; Migliari R; De Lisa A; Campus G; Usai E
    Minerva Urol Nefrol; 1988; 40(2 Suppl):18-20. PubMed ID: 2460939
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
    Re G; Badino P; Odore R; Vigo D; Bonabello A; Rabino S; Capello F; Bruzzese T
    Pharmacol Res; 2001 Aug; 44(2):141-7. PubMed ID: 11516265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mepartricin in the treatment of benign prostatic hyperplasia].
    Cirillo Marucco E; Pagliarulo A; Piccinno A; Di Rienzo U
    Minerva Urol Nefrol; 1988; 40(2):101-4. PubMed ID: 2459784
    [No Abstract]   [Full Text] [Related]  

  • 10. [Latest contribution concerning the use of mepartricin in adenoma of the prostate].
    Comar OB; Di Rienzo A
    Minerva Urol Nefrol; 1988; 40(2 Suppl):30-2. PubMed ID: 2460944
    [No Abstract]   [Full Text] [Related]  

  • 11. [Mepartricin versus placebo in the therapy of prostatic hypertrophy].
    Fini M; Perrone A; Ferraresi R; Salvi G; Misuriello G; Vagliani GF
    Minerva Urol Nefrol; 1988; 40(2 Suppl):53-4. PubMed ID: 2460953
    [No Abstract]   [Full Text] [Related]  

  • 12. [Mepartricin in prostatic hypertrophy. Results in 20 cases].
    Durval A; Rovereto B; Tosto A; Paoletti MC; Natali A; Pellegrini GL
    Minerva Urol Nefrol; 1986; 38(1):81-5. PubMed ID: 2426804
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of mepartricin, a polyene macrolide agent, on fecal excretion and serum concentration of estrogen and number of prostatic estrogen receptors in immature rats.
    Shakutou S; Bandoh K; Yoshinaka Y; Kobayashi H; Yamanaka H
    Prostate; 1999 Jan; 38(1):17-27. PubMed ID: 9973105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The role of mepartricin in the medical treatment of benign prostatic adenoma].
    Casella G; Barbaro A
    Arch Sci Med (Torino); 1978; 135(1):95-8. PubMed ID: 76466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical experience with mepartricin in the treatment of prostatic hypertrophy. Preliminary results].
    Bassi P; Oliva G; Tasca A; Aragona F; Milani C; Zattoni F
    Minerva Urol Nefrol; 1988; 40(2 Suppl):40-3. PubMed ID: 2460948
    [No Abstract]   [Full Text] [Related]  

  • 16. [Use of mepartricin in the treatment of benign prostatic hypertrophy. Evaluation of clinical and functional parameters].
    Petrone U; Gaspari G; Magnocavallo N; Petrone D; Tucci C; Marascia G
    Minerva Urol Nefrol; 1988; 40(2):89-91. PubMed ID: 2459785
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prolonged medical therapy using mepartricin in prostatic hypertrophy. Results in 81 patients].
    Serretta V; Pavone C; Di Trapani D; Romano C; Costa G; Caramia G
    Minerva Urol Nefrol; 1988; 40(2 Suppl):55-8. PubMed ID: 2460954
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mepartricin in the treatment of prostatic hypertrophy and correlated sexual disorders].
    Buffa G; Brigato R; Cocimano V; Cevoli R; Marino G
    Minerva Urol Nefrol; 1987; 39(2):121-4. PubMed ID: 2442818
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of mepartricin (S-160) on spontaneous canine benign prostatic hyperplasia.
    Yoshinaka Y; Kobayasi H; Kirihara J; Sato F; Shakutou S; Yamanaka H
    Eur Urol; 2000 Apr; 37(4):428-35. PubMed ID: 10765073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of mepartricin in the treatment of benign prostatic hypertrophy. Open study of 39 patients].
    Montanari E; Patelli E; Mandressi A; Magri V; Pisani E
    Minerva Urol Nefrol; 1988; 40(2 Suppl):25-9. PubMed ID: 2460942
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.